CRBP vs. CGEM, TNXP, ITOS, GOSS, RGNX, PRTA, TECX, EOLS, PRTC, and REPL
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), iTeos Therapeutics (ITOS), Gossamer Bio (GOSS), REGENXBIO (RGNX), Prothena (PRTA), Tectonic Therapeutic (TECX), Evolus (EOLS), PureTech Health (PRTC), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.
Corbus Pharmaceuticals vs. Its Competitors
Corbus Pharmaceuticals (NASDAQ:CRBP) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals has a beta of 3.2, meaning that its share price is 220% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500.
Corbus Pharmaceuticals presently has a consensus price target of $49.00, suggesting a potential upside of 368.00%. Cullinan Therapeutics has a consensus price target of $26.80, suggesting a potential upside of 237.96%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Cullinan Therapeutics.
64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cullinan Therapeutics' return on equity of -36.56% beat Corbus Pharmaceuticals' return on equity.
In the previous week, Cullinan Therapeutics had 13 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 17 mentions for Cullinan Therapeutics and 4 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.54 beat Cullinan Therapeutics' score of 1.04 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.
Summary
Corbus Pharmaceuticals beats Cullinan Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRBP) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access